To summarize the current evidence on available screening programs for renal cell carcinoma (RCC), focusing on their potential benefits, harms, and impact on clinical practice, particularly through a systematic review approach.
Key Findings:
RCC incidence is rising, with significant mortality rates, highlighting the need for effective screening, with over 430,000 new cases diagnosed annually.
Focused renal ultrasound is a cost-effective tool for early detection, but other non-invasive modalities lack clinical validation.
Screening programs could improve early detection and reduce healthcare costs, but concerns about overdiagnosis and psychological distress exist, necessitating careful implementation.
Interpretation:
Screening programs for RCC could enhance early detection and treatment, potentially improving survival outcomes and quality of life; however, further research is essential to address uncertainties regarding their implementation and effectiveness.
Limitations:
Uncertainties about the benefits of early treatment and overall cost-effectiveness of screening, which may affect clinical decision-making.
Potential harms of screening, including overdiagnosis and financial toxicity, which could impact patient well-being and healthcare resources.
Conclusion:
While screening programs for RCC show promise, careful consideration of their design and implementation is essential to maximize benefits and minimize risks, particularly in light of the identified limitations.
